Xeris Pharmaceuticals Inc (XERS) — Capital Reinvestment Ratio

Latest as of June 2026: 0.03x

Xeris Pharmaceuticals Inc (XERS) has a Capital Reinvestment Ratio of 0.03x as of June 2026, meaning it reinvests 0% of its operating cash flow ($8.26 Million) in capital expenditures ($209.00K). Check XERS tangible net assets ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.03x
Capex / Operating Cash Flow

Operating Cash Flow

$8.26 Million
USD

Capital Expenditures

$209.00K
USD

Data as of

Jun 2026
Most recent filing

Xeris Pharmaceuticals Inc Capital Reinvestment Ratio (2025–2025)

This chart tracks Xeris Pharmaceuticals Inc's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see Xeris Pharmaceuticals Inc (XERS) cash flow conversion.

Annual Capital Reinvestment Ratio for Xeris Pharmaceuticals Inc (2025–2025)

Year-by-year Capital Reinvestment Ratio for Xeris Pharmaceuticals Inc from 2025 to 2025. See free cash flow generation of Xeris Pharmaceuticals Inc to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2025 0.02x $28.63 Million $696.00K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow